SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma informs about newspaper publication

02 Feb 2026 Evaluate
Pursuant to Regulation 47 of the Listing Regulations, Ajanta Pharma has informed that it enclosed copies of financial results of the Company for the quarter and nine months ended 31st December 2025 published in newspapers, Mumbai edition of Business Standard and Mumbai edition of Navakal on 31st January 2026.

The above information is a part of company’s filings submitted to BSE.

Ajanta Pharma Share Price

2770.00 -9.20 (-0.33%)
24-Apr-2026 10:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1626.85
Dr. Reddys Lab 1310.70
Cipla 1288.10
Zydus Lifesciences 925.05
Lupin 2300.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×